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Abstract In the last years of the previous century the genes involved in the aetiology of ®ve endocrine
tumour syndromes have been identi®ed. The tumour-suppressor gene that is responsible for
Von Hippel±Lindau Disease was cloned in 1993; multiple endocrine neoplasia (MEN) types
2A and 2B and familial medullary thyroid carcinoma were found to be caused by activating
mutations in the ret proto-oncogene in 1993 and 1994, and most recently the menin-gene,
another tumour-suppressor gene, was shown to be associated with MEN-1. As usual, the
answer to one question leads to innumerable new questions. And so, now we want to know
the extent to which germ-line mutations (de novo, or otherwise previously undetected) in
these genes play a role in the occurrence of the various endocrine tumours that are associated
with these syndromes in apparently sporadic cases. We also want to know if the nature of the
(germ-line) mutation conveys any information about the characteristics (phenotype) of the
disease. We want to know the role of somatic mutations in these genes in truly sporadic
tumours. And ®nally we want to know the exact function of the proteins that are encoded by
these genes. The paper by Roijers et al. [1] elsewhere in this issue is an example of a small but
well-directed step on the way to address some of these questions with respect to the menin-
gene. It addresses the problem of patient selection when looking for germ-line mutations in
apparently sporadic MEN-1 patients. In this review we want to give a brief summary of the
present status with regard to some of the questions mentioned above, in relation to the
endocrine tumour syndromes caused by the vhl, ret and menin genes.
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Introduction
Between 1993 and 1997 the genes involved in a number of
hereditary endocrine tumour syndromes have been identi-
®ed. Von Hippel±Lindau Disease (VHL) was shown in
1993 to be caused by inactivating mutations in the vhl
tumour-suppressor gene (gene map locus 3p26-p25) [2].
Also in that year, a speci®c set of activating mutations in the
ret proto-oncogene (10q11.2) were found in most families
with the multiple endocrine neoplasia type 2A syndrome
(MEN-2A) [3]. In the same year the same mutations were
shown to be the cause also of familial medullary thyroid
carcinoma (FMTC) [4]. A year later, in 1994 the ret proto-
oncogene was also implicated in MEN-2B [5,6], albeit that
a different activating mutation in a different region of the
gene was involved here. Finally, in 1997, the menin tumour-
suppressor gene (11q13) [7,8] was identi®ed as the affected
gene in MEN-1 families.
The identi®cation of these genes has led to a consider-
able amount of research trying to elucidate the role of these
genes and the way in which their activation (ret) or inacti-
vation (vhl, menin) leads to cancer in speci®c organs. There
has also been much interest in the question whether these
genes are also involved ÿ through somatic mutations ÿ in
the sporadic analogues of the tumours that occur in these
®ve syndromes. Last, but not least, there is the question of
case ®nding. In all these genes new germ-line mutations
can occur, thus creating new families at risk. In various
papers the frequency of de novo germ-line mutations in
these genes in patients with apparently sporadic endocrine
tumours is estimated to be somewhere between 3 and 7%
of the cases [9±11]. The question is how to proceed in
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order to identify these new cases of hereditary disease
among the vast majority of sporadic cases. In a paper in
this issue Roijers et al. [1] describe their efforts to narrow
down the ®eld, in their search for new cases of MEN-1.
Von Hippel±Lindau disease
VHL (MIM 193300) is characterized by the familial
occurrence of tumours in a large number of organs and
organ systems. The most important of these are clear cell
renal tumours, pheochromocytomas, retinal angiomas and
cerebellar and spinal haemangioblastomas. Since the iden-
ti®cation of the vhl-gene [2], 200 different mutations have
been identi®ed in affected families (and recorded in The
Human Gene Mutation Database http://http://www.uwcm.
ac.uk/uwcm/mg/hgmd0.html [12]). These mutations can
roughly be divided into two classes: ®rst, mutations result-
ing in a truncated, inactive or absent protein, arising from
the occurrence of premature termination codons through a
variety of mechanisms (nonsense mutations, insertions and
deletions associated with frameshifts, and gross deletions);
and second, missense mutations. The ®rst class is pre-
dominantly associated with clear-cell renal carcinoma,
retinal angioma and cerebellar and spinal haemangioblas-
toma, while in the second class these tumours also occur,
but are now often accompanied by phaeochromocytomas
[13,14]. In addition to these two classes, vhl-alleles are
found, which result in the occurrence of phaeochromo-
cytomas alone [15]. Further indications that there exists a
strong genotype±phenotype relationship for vhl-alleles is
found in the observation that identical mutations in Cau-
casian and Japanese VHL-families produce similar cancer
phenotypes [15]. Somatic mutations in the vhl-gene have
been found in 10 out of 20 capillary haemangioblastomas
of the central nervous system [16]. In two of these 10
patients the same mutations were also found in lymphocyte
DNA, indicating that these two patients carried (new?)
germ-line mutations in the vhl-gene. In a number of recent
studies [17±19], somatic mutations were identi®ed in more
than 50% of the sporadic (non-papillary) renal cell carci-
nomas. From one of these studies it also appeared that
these mutations were predominantly of the same class
(protein-truncating mutations) as those that confer type 1
VHL in the case of germ-line mutations [18]. From a
literature study these authors also conclude that in the
case of VHL such mutations not only reduce the chance of
the occurrence of a phaeochromocytoma, but also increase
the chance of renal cell carcinoma. On the basis of clinical
observations Neumann et al. [20] suggested that apparently
sporadic pheochromocytomas are frequently part of VHL
(19%) or MEN-2 (4%). More recent studies [10,21±23]
have shown that only in 5±10% of the patients presenting
with phaeochromocytoma germ-line mutations in the vhl-
gene could be detected. The discrepancy may be solved by
the observation that in the group of people studied initially
[20] a founder-effect was later (after the vhl-gene had been
cloned) identi®ed [24].
The VHL-protein is widely expressed [2,25] and exists
in two forms of 213 and 160 amino acids, respectively, the
second form originating from an internal translation initia-
tion site [26,27]. Its function has not yet been elucidated
completely, but is associated with the regulation of trans-
cription elongation by RNA polymerase II [28]. Transcrip-
tion elongation is stimulated by the multimeric protein
complex elongin [29,30], and the intact VHL-protein can
inhibit elongin activity by sequestering the B and C sub-
units of the elongin complex. More speci®cally the VHL-
protein appears to be involved in the down-regulation of
the expression of vascular endothelial growth factor
[31,32], an observation that corresponds well with the
highly vascularized nature of most VHL-associated
tumours. Interestingly mutations in one of the few `hot-
spots' for vhl-mutations, codon 167 [15], were found to
coincide with the loss of elongin-binding capacity by the
VHL-protein [28].
Multiple endocrine neoplasia type 1
MEN-1 (MIM 131100) is a dominantly inherited endo-
crine cancer syndrome, characterized by the occurrence of
parathyroid adenomas, pituitary adenomas, adrenocortical
adenomas, tumours of the endocrine pancreas, duodenal
gastrinomas and carcinoid tumours. In 1997 the gene
responsible for MEN-1, the menin-gene, localized on chro-
mosome 11q13, was cloned [7,8]. The gene is organized in
10 exons and codes for a widely expressed 610 amino acid
protein (menin) that bears no resemblance to other known
proteins, making predictions about its function more dif®-
cult. Menin has been shown to be a nuclear protein [33],
and it is probably involved in the regulation of transcription
via interactions with the transcription factor JunD [34].
The tumour-suppressor nature of the menin-gene has since
then been con®rmed by mutational analysis in MEN-1
families, revealing more than 100 different inactivating
mutations (e.g [35±37] and the Human Gene Mutation
Database [12]). Interestingly, there seem to be a number of
hotspots for deleterious mutations in the gene. These sites
appear to be located at positions where the nucleotide
sequence is prone to undergo replication errors, e.g. due
to slipped-strand mispairing [37,38] rather than at posi-
tions coding for amino acids essential for the function of the
protein. Furthermore, a wide variety of missense and
nonsense mutations, evenly distributed all over the gene
has been identi®ed. While the original descriptions of the
MEN-1 syndrome placed much emphasis on the intra-
familial homogeneity of the phenotype, it has now become
clear that such a genotype±phenotype relationship is rare in
the case of MEN-1 [36,37,39]. However, irrespective of
the phenotype, the MEN-1 syndrome appears to be highly
penetrant. On the basis of a large group of patients, Basset
et al. calculated an age-related penetrance of 98% by 40
years of age, increasing to 100% by 60 years of age [36,40],
but lower percentages have also been found [41]: 50%
penetrance at 50 years of age. Studies in a large kindred
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[42] suggest that the phenotype ÿ as represented by the
type of tumours occurring, the age of onset and the
penetrance ÿ is more dependent upon the genetic environ-
ment than upon the nature of the menin mutation. This is
illustrated by the observation that the phenotype in differ-
ent branches of one large family showed considerable
differences [42]. Somatic mutations in the menin-gene
have been found in 20±30% of the sporadic parathyroid
tumours [43] but not in familial hyperparathyroidism [35].
In sporadic insulinomas/gastrinomas [44,45] and in spora-
dic lung carcinoids [46] a considerable number of the
tumours also show somatic mutations in the menin-gene.
Despite extensive screening of large numbers of tumours,
no mutations in the menin-gene have been found in
sporadic pituitary tumours [47], nor in sporadic adrenal
neoplasms [48±50].
Multiple endocrine neoplasia type 2A and 2B
and familial medullary thyroid carcinoma
MEN-2A (MIM 171400), MEN-2B (MIM 162300) and
FMTC (MIM 155240) form a typical example of clinically
different syndromes, all caused by mutations in the same
gene. The three syndromes are dominantly inherited and
their common denominator is the occurrence of medullary
thyroid carcinoma, alone in the case of FMTC, or accom-
paniedbyphaeochromocytomas and parathyroid hyperplasia
(MEN-2A), or phaeochromocytomas, mucosal neuromas
and developmental abnormalities (MEN-2B). The ret-
gene was identi®ed as a proto-oncogene in 1985 [51] by
®nding it rearranged in an NIH3T3 transfection assay,
hence its name: REarranged during Transfection. Interest-
ingly, before its involvement in MEN-2 became apparent, it
had already been shown that the ret-gene played a role in
(sporadic) papillary thyroid carcinoma [52]. In contrast to
the menin- and vhl-tumour suppressor genes, the ret-gene is
a proto-oncogene. The activating mutations that have been
identi®ed in this gene in MEN-2 and FMTC are of two
types. In approximately 96% of the MEN-2A and FMTC
families, any one of ®ve cysteine residues (609, 611, 618,
620 or 634) was found to be mutated [3,4,53±56] (Fig. 1).
In 95% of the MEN-2B families a methionine to threonine
mutation was identi®ed in codon 918 [5,6,53] (Fig. 1).
The effects of the ret-mutations in MEN-2A, MEN-2B and
FMTC are closely related to the function of the RET-
protein. RET is a receptor protein with tyrosine-kinase
activity. Together with the co-receptor, glial-cell-derived
neurotrophic factor receptor-a, (GDNF-Ra), it takes care
of the intracellular transmission of the GDNF signal [57±59].
The signalling cascade involves binding of GDNF to the
GDNF-Ra, two copies of liganded GDNF-Ra then recruit
two copies of RET, which upon dimerization auto-
phosphorylate and thus initiate the intracellular signalling
chain [57±59]. The abrogation of one of the extracellular
cysteine residues that occurs in MEN-2A and FMTC,
possibly results in ligand-independent auto-dimerization
of the RET-protein with constitutive activation as the
oncogenic consequence [60±63]. Genotype±phenotype
relationships exist in MEN-2A, although they are not
absolute. In a very large study, comprising 477 MEN-2
and FMTC families [53], mutations in codon 634 were
found to be strongly associated with the occurrence of
medullary thyroid carcinoma in combination with phaeo-
chromocytoma. On the other hand the presence of muta-
tions in one of the other codons showed a strong correlation
with the combination of medullary thyroid carcinoma and
HPT [53].
In MEN-2B the replacement of methionine 918 of the
RET-protein by a threonine residue, located within the
tyrosine kinase domain of the protein, has been shown to
affect the substrate speci®city of the kinase activity [62,64].
While tyrosine kinases with methionine residues at a similar
position in the active site typically phosphorylate tyrosine
residues of membrane-bound substrates, threonine resi-
dues at this position lead to speci®city for soluble (protein)
substrates such as src and abl [64].
Searching mutations
In the previous sections we have tried to give an overview of
the genetic causes of the MEN syndromes and VHL
disease. Here we want to consider some of the aspects
that come to mind when the question is asked if it makes
sense to look for mutations in the genes involved in these
tumour syndromes in patients. In this respect we would like
to distinguish three groups: ®rst, members, known or not
known to be affected, of MEN and VHL families; second,
patients, not known to be members of such families,
presenting with (apparently) sporadic tumours associated
with these syndromes; and third, somatic mutations in the
sporadic analogues of tumours that are also associated with
these syndromes.
Many of the issues discussed here have been addressed in
two papers in a recent issue of Science by Fearon [65] and
Ponder [9].
Families
With the identi®cation of the responsible genes, speci®c
mutations causing the disease have been found in many
MEN and VHL families. Without wanting to underesti-
mate the psychological and ethical factors involved [9], we
feel that both the potential patients and their families and
society bene®t from the identi®cation of family members
who are carriers of these mutations. A `poll' held at a recent
meeting on MEN and VHL suggests that the majority of
clinicians share this opinion [66]. With regard to the MEN-
2A syndrome, a striking example of the bene®ts of such
mutational screening, as compared to clinical and biochem-
ical screening, was presented by Lips et al. [67]. The paper
illustrates that the clinical and biochemical screening
for MEN-2 result in false positives (and unnecessary
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thyroidectomies) but also in an alarming number of false
negatives and increased risk for the patients. Moreover,
when the speci®c mutation associated with the disease has
been identi®ed in a family, screening family members `at
risk' is relatively easy because the target is known, and
simple techniques, such as restriction fragment length
polymorphism analysis, allele speci®c hybridization, or
single strand conformation polymorphism (SSCP) can be
used. This type of screening should be carried out at an age
lower than the lowest age reported for the ®rst occurrence
of the ®rst manifestations of these tumour syndromes [66].
In this respect, the age of 10 years is usually mentioned.
However, in MEN-2 and FMTC some authors suggest that
thyroidectomy should be performed as early as at the age of
5 years [68], especially in the case of MEN-2B where
medullary thyroid carcinoma is known to have an earlier
age of onset and a more aggressive nature. Parenthetically,
this observation is widely mentioned with regard to MEN-
2B, but we could ®nd no speci®c reference to it in the
literature. The advantages of such screening are obvious: in
the case of MEN-2 and FMTC prophylactic thyroidect-
omy will prevent metastatic disease, and thus eliminate the
most important source of disease in the patients. For all
other manifestations of MEN-2 well-directed clinical sur-
veillance may prevent the disease from getting out of hand.
With regard to the tumour-suppressor genes menin and
vhl the situation is more complex. To ®nd a mutation in
these genes in clinically recognized families usually means
that the whole gene (coding sequence, including splice
sites) has to be sequenced in at least one affected
member of the family. If a mutation is identi®ed, it has to
be shown to be related to the presence of the syndrome.
This means that either it has to be shown to segregate with
the disease, which means that a number of affected and
unaffected family members must be available for screening,
or the other allele has to be shown to be destroyed also in
the tumour tissue. While mutations that result in a trun-
cated protein are generally assumed to be deleterious,
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Figure 1 The organization of the ret-gene, mRNA, and protein,
and the position of the amino acid residues mutated in multiple
endocrine neoplasia type 2A (MEN-2A), familial medullary
thyroid carcinoma (FMTC) and MEN-2B. S, signal peptide;
Cd, cadherin-like domain; Cys, cysteine-rich domain; TM,
trans-membrane domain; TK, tyrosine-kinase domain.
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missense mutations pose a greater problem, in this respect,
because due to the lack of knowledge about the exact
function of these proteins functional tests are not available
at present. In the case of the menin-gene, however, the
extraordinary degree of evolutionary conservation of the
gene between humans and rodents [69±72] and the relative
lack of amino-acid polymorphisms in the protein genome
database (GDB), suggests that most, if not all amino-acid
changes may be deleterious. Once a mutation has been
found and shown to be responsible for the presence of
the syndrome, however, looking for the presence or
absence of the mutation can screen other members of
the family relatively simply. In contrast to the situation in
MEN-2 and FMTC, however, there are no obvious
prophylactic measures that can be taken in VHL and
MEN-1 carriers, and careful follow-up of these patients is
the only option. In VHL the organs at which to look most
speci®cally may be indicated on the basis of the genotype±
phenotype relationship described above, but in MEN-1
the apparent lack of such relationships and the intra-
familial diversity of the phenotype dictates the utmost
care.
Germ-line mutations in apparently sporadic cases
In all the syndromes described in this review, new heredi-
tary cases can arise by de novo germ-line mutations. The
frequency of the occurrence of germ-line mutations in
apparently sporadic tumours associated with these syndromes
has been reported to be in the range of 3±7% [9±11]. In some
cases, however, higher percentages have been found, e.g. germ-
line MEN-1 mutations in 25% of thymic carcinoids [73].
Screening for the limited number of possible mutations
associated with the MEN-2 syndromes and FMTC is
probably economically and practically feasible in all
patients presenting with apparently sporadic medullary
thyroid carcinoma or phaeochromocytoma (see Fig. 2).
In the case of MEN-1 and VHL such an approach is not
possible because it would in actual practice involve com-
plete sequence analysis of at least the coding region of the
genes involved. Therefore, it is necessary to apply selection
criteria to these patient populations in order to increase the
detection rate. For MEN-1, Roijers et al. [1] describe such
a set of criteria. They have analysed, by complete sequencing
of the menin-gene, 15 MEN-1 suspected patients ful®lling
Figure 2 Schematic representation of the mutation detection
procedures in possible multiple endocrine neoplasia type 2
(MEN-2) and familial medullary thyroid carcinoma (FMTC)
patients. Polymerase chain reaction-ampli®cation of a fragment
containing the relevant sequences of exons 10 and 11 is followed
by sequence analysis using internal primers (a). This procedure
analyses the codons 609, 611, 618 and 620 in exon 10 and
codon 634 in exon 11, all involved in MEN-2A and FMTC.
Polymerase chain reaction-ampli®cation of exon 16, followed by
treatment with the restriction enzyme FokI discriminates between
carriers and non-carriers of the M918T mutation involved in
MEN-2B because the mutation eliminates a FokI site (b).
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the criteria `young (<35 years) age at onset and/or multiple
MEN-1 related lesions in a single organ or two distinct
organs affected'. They identi®ed mutations in nine of 15
patients (60%), which is considerably more that the 3±7%
that is found in unselected patients. Assuming that these
nine mutation-positive patients represent the expected 5% of
the total population presenting with MEN-1-related symp-
toms, it can be seen that the ef®ciency of this set of criteria
is huge: 15 sequence analyses instead of 180. It will be
interesting to see in 5±10 years what has happened to the
165 patients that were excluded (but granted a clinical
follow-up). Sequence analysis of the whole coding region of
the menin-gene in selected patients (as above) is probably
the best option available at present. We should, however,
keep in mind that currently unde®ned regulatory sequences,
involved in the expression of this gene may also be involved
in MEN-1, and that splicing, despite the existence of
de®ned splice-consensus sites, may still be found to pro-
ceed in ways that have not been identi®ed completely.
For VHL-related tumours a similar study has not yet
been reported, but it is likely that the same or a similar set
of criteria will be useful in the discrimination between
patients with new germ-line mutations and those with
truly sporadic tumours.
Somatic mutations
Two reasons exist for searching for somatic mutations in
genes associated with cancer syndromes in (truly) sporadic
tumours. First, knowledge about the mechanisms of tumour
development and about structure±function relationships in
the proteins involved can be gained from such investiga-
tions. Second, it is sometime useful to identify these muta-
tions because their nature may have consequences for the
treatment or prognosis of the tumour. With respect to the
®rst point, there is the observation that in sporadic medul-
lary thyroid carcinoma somatic mutations of the MEN-2B
type (methionine 918 ! threonine) have been found to
occur much more frequently than those associated with
MEN-2A [21,74,75]. This suggests that the substrate-
speci®city of the RET tyrosine kinase activity ÿ which is
changedby theM918Tmutationÿplaysa morecrucial role in
tumour formation than constitutive activation which occurs
due to the MEN-2A mutations. It has indeed been suggested
that in the mature thyroid gland such activation, which mimics
the normal activation of the receptor, has no effect [76].
A (negative) example with regard to the second point is
formed by the observation that there appears to be no
difference between the behaviour of medullary thyroid
carcinomas that have a somatic MEN-2B mutation and
those that do not have a mutation in the ret-gene.
Conclusions
A minor proportion of sporadic endocrine tumours, estimated
at approximately 6%, are in fact de novo manifestations of
the endocrine tumour syndromes MEN-1, MEN-2 and
VHL. While it is feasible to investigate the patients with
MEN-2-associated tumours for mutations in the ret-gene,
because a limited number of known mutations in this
proto-oncogene is associated with the MEN-2 syndromes,
this is much more dif®cult in the case of MEN-1- and
VHL-associated tumours. This is due to the fact that these
two genes are tumour-suppressor genes, and any inactivat-
ing mutation in these genes may be the cause of the
syndrome. A set of criteria for the selection of patients for
whom mutation analysis is especially useful, such as
recently described for MEN-1 [1], can signi®cantly reduce
the amount of work involved, and contributes to improved
diagnostic possibilities. Future research, especially aimed at
the elucidation of the function of the menin gene may further
contribute to identify the mechanism that underlies the
formation of tumours when this gene is inactivated. It will
be especially interesting to see why this gene ÿ besides its
involvement in the MEN-1 syndrome ÿ is also involved in
tumorigenesis in some, but not all types of sporadic
tumours that are also associated with MEN-1.
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